Description Usage Format References
Survival data from a trial comparing chemotherapy versus atezolizumab in the treatment of Urothelial carcinoma.
1 |
A data frame with 625 observations (316 in the atezolizumab group and 309 chemotherapy group) with the following 3 columns:
the observed follow-up times in days.
the event indicators, 0=right censored, 1= event.
the group labels, 1 = atezolizumab, 2 = chemotherapy.
Powles T, Dura?n I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748-757.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.